Related Experiment Video
Updated: May 11, 2026

Identification and Analysis of Mouse Erythroid Progenitors using the CD71/TER119 Flow-cytometric Assay
Published on: August 5, 2011
Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary
Konrad Aumann1, Anna-Verena Frey, Annette M May
1Institute of Pathology, University Medical Center Freiburg, Freiburg, Germany.
Abstract:
The World Health Organization (WHO) classification of myeloproliferative neoplasms (MPNs) comprises several entities including essential thrombocythemia (ET); primary myelofibrosis (PMF); and MPN, unclassifiable (MPN,U). Differential diagnosis between ET and early, prefibrotic PMF can be challenging but is critical because clinical course and outcome vary considerably between these entities. We have previously shown that the transcription factor nuclear factor erythroid 2 (NF-E2) is aberrantly expressed in MPN patients. Here we demonstrate that NF-E2 is mislocalized in PMF cells and that aberrant NF-E2 localization discriminates statistically highly significantly between ET and PMF. A threshold of 20% nuclear NF-E2 staining was cross-validated by ".682+ bootstrapping." Moreover, this cutoff correctly classifies diagnostic bone marrow biopsies of MPN,U patients specified upon follow-up as ET or PMF with 92% accuracy. Because interobserver concordance between independent pathologists was high (Spearman's rank correlation coefficient, 0.727), we propose that quantitative NF-E2 immunohistochemistry represents a diagnostic tool that can reliably support a differential diagnosis between ET and PMF.
Insights
Nuclear factor erythroid 2 (NF-E2) mislocalization in myeloproliferative neoplasms (MPNs) distinguishes essential thrombocythemia (ET) from primary myelofibrosis (PMF). This finding supports NF-E2 immunohistochemistry as a reliable diagnostic tool for MPN classification.
Area of Science:
- Hematology
- Oncology
- Molecular Pathology
Background:
- The World Health Organization (WHO) classification categorizes myeloproliferative neoplasms (MPNs) into essential thrombocythemia (ET), primary myelofibrosis (PMF), and MPN, unclassifiable (MPN,U).
- Distinguishing between ET and early, prefibrotic PMF is clinically significant due to differing prognoses, yet can be diagnostically challenging.
- Aberrant expression of the transcription factor nuclear factor erythroid 2 (NF-E2) has been previously observed in MPN patients.
Purpose of the Study:
- To investigate the diagnostic utility of nuclear factor erythroid 2 (NF-E2) localization in differentiating ET from PMF.
- To establish a quantitative threshold for NF-E2 nuclear localization to support differential diagnosis in MPNs.
Main Methods:
- Immunohistochemistry was employed to assess NF-E2 localization in bone marrow biopsies from MPN patients.
- Quantitative analysis of nuclear NF-E2 staining was performed.
- Statistical analysis, including bootstrapping and interobserver concordance assessment, was utilized to validate findings.
Main Results:
- Aberrant NF-E2 mislocalization was observed in PMF cells compared to ET cells.
- A threshold of 20% nuclear NF-E2 staining demonstrated high statistical significance in discriminating between ET and PMF.
- This NF-E2 staining cutoff achieved 92% accuracy in classifying MPN,U cases upon follow-up and showed high interobserver concordance (Spearman's rho = 0.727).
Conclusions:
- Quantitative NF-E2 immunohistochemistry is a reliable tool for supporting the differential diagnosis between ET and PMF.
- NF-E2 mislocalization serves as a significant biomarker for distinguishing these MPN subtypes.
- This method offers a valuable adjunct to existing diagnostic criteria for MPNs.
Related Concept Videos
Master Transcription Regulators
Erythropoiesis
Transcription Factors
General Transcription Factors
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...

